Stefan Constantin Ionel sold $307K of AMPX

Stefan Constantin Ionel (Chief Technology Officer) sold 29,681 shares of Amprius Technologies, Inc. (AMPX) at $10.34 ($0.31M total) on 2026-08-21.

Original reporting
SEC EDGAR · Stefan Constantin Ionel
Published Aug 25, 2026, 9:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AMPX
Neutral
high confidence
Mentioned
$AMPX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMPXNeutralLow
01

Why it matters

Limited impact; insider sale under $1M typically has minimal market effect.

02

Market read

Routine insider transaction with low trading relevance.

03

What to watch

Potential upcoming financing or strategic changes not disclosed.

Relevance 4/10Novelty 4/10Timing: filing date 2026-08-25

Background

SEC Form 4 filing reporting insider sale by Amprius Technologies CTO.

Company-level read

Ticker impact

$AMPXNeutralHigh confidence
Context

CTO Stefan Constantin Ionel sold 29,681 shares for $306,931, reducing his stake to 771,629 shares.

Expected impact

No significant move expected.

Evidence & confidence

Sale size is modest relative to float and disclosed as a routine transaction.

Market effects

None

None

None

Counterpoint

Sale could signal insider concerns, but size is too small to infer.

Key entities

  • Amprius Technologies, Inc.

    US-listed battery technology company.

  • Stefan Constantin Ionel

    Chief Technology Officer of Amprius.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AMPXMedAI 8/10

Amprius (AMPX) Q3 2026 Earnings Call Transcript

Amprius reported Q3 2026 revenue of $39.1M, up 83% YoY, raising its full-year target to $145M. The company introduced SiCore 500 cells for aviation and secured a $75M U.S. defense contract. Amprius expanded into maritime vehicles and partnered with U.S. manufacturers for NDAA-compliant production.

$AMPXMedAI 8/10

Amprius Technologies Q3 Earnings Call Highlights

Amprius reported a Q3 net loss of $3.5M, with adjusted EBITDA at -$1M. The company maintained its full-year gross margin forecast of 28% and expects Q4 sales of $43.3M. Amprius is expanding manufacturing to meet demand, with a $75M contract for a U.S. battery production line. It also introduced new products for aviation and deep-sea applications, ending Q3 with $60.7M in cash.

$AMPXHigh

Amprius Technologies falls 7% on third quarter earnings miss

Amprius Technologies (NYSE:AMPX) reported Q3 earnings missing estimates with a loss of $0.02 per share, though revenue of $39.1M beat expectations. Shares fell 7.7% after-hours. The company raised its full-year 2026 revenue outlook to $145M, above analyst forecasts. Gross profit rose 217% YoY to $10.5M, with gross margin improving to 27%. Amprius secured a $75M U.S. Department of War contract and introduced a new battery cell.

$AMPXMed

Amprius Technologies Reports Third Quarter 2026 Financial Results and Recent

Amprius Technologies, Inc. (AMPX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Amprius Technologies Reports Third Quarter 2026 Financial Results and Recent Business Highlights • Q3 2026 revenue increased 83% year-over-year to $39.1 million • Net loss of $3.5 million, a 10% year-over-year improvement • Increasing 2026 revenue outlook to $145 mil

$AMPXHigh

AMPX Stock Jumps As Defense Deals Supercharge Growth Story

Amprius Technologies Inc. (NYSE: AMPX) shares rose 8.38% on October 21, 2026, driven by U.S. Department of War funding and a partnership with Caminus for battery production. The company secured $75M in funding for a high-energy-density cell plant, with revenue growth but negative margins. Canaccord Genuity initiated coverage with a Buy rating and $14 price target.